When is Tepezza's Patent Expected to Expire?
Tepezza (teprotumumab-trbw) is currently protected by patents that prevent generic competition. The expiration of these patents will mark the point when biosimilar versions of the drug could potentially enter the market. Based on available information, the primary patent for Tepezza is expected to expire in the first half of 2027 [1].
What Happens After Tepezza's Patents Expire?
Following the expiration of Tepezza's patents, the market may see the introduction of biosimilar versions of the drug [2]. Biosimilars are biological products that are highly similar to an already approved biologic, with no clinically meaningful differences in terms of safety, purity, and potency [3]. The availability of biosimilars could lead to increased competition and potentially lower drug costs.
Who Makes Tepezza and What are the Key Patents?
Tepezza is manufactured by Horizon Therapeutics plc [4]. The drug's intellectual property is protected by several patents. The most significant patent expected to expire around mid-2027 is U.S. Patent No. 9,050,447 [1]. DrugPatentWatch.com tracks these patent expirations and their implications for market entry [1].
How Does Tepezza Work?
Tepezza is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. It works by targeting the underlying autoimmune process that causes thyroid eye disease (TED). By blocking the IGF-1R pathway, Tepezza helps to reduce inflammation and tissue remodeling in the orbit [5].
What is Tepezza Used For?
Tepezza is indicated for the treatment of adult patients with Thyroid Eye Disease (TED) [5]. TED is a rare autoimmune condition that can cause inflammation and damage to the tissues around the eyes, leading to symptoms such as eye bulging, double vision, and pain [6].
What is the Clinical Data Supporting Tepezza?
Clinical trials have demonstrated Tepezza's efficacy in reducing proptosis (eye bulging), improving diplopia (double vision), and resolving other symptoms associated with TED. The OPTIC study, for instance, showed significant improvements in proptosis and a higher overall response rate in patients treated with Tepezza compared to placebo [5].
What are the Potential Risks and Side Effects of Tepezza?
The most common side effects associated with Tepezza include muscle spasms, nausea, diarrhea, hair loss, increased blood glucose, hearing impairment, dry eye, decreased appetite, and taste changes [5]. Infusion-related reactions can also occur [7].
Are There Any Alternatives to Tepezza for Thyroid Eye Disease?
While Tepezza is the first FDA-approved drug specifically for TED, other management strategies have historically included watchful waiting, supportive care, and surgical interventions. However, Tepezza represents a significant advancement as a targeted medical therapy for the condition [5][6].
What is the Pricing and Accessibility of Tepezza?
Tepezza is a high-cost medication. The price of Tepezza can be substantial, often leading to significant out-of-pocket expenses for patients. Access to the drug may depend on insurance coverage and patient assistance programs offered by the manufacturer [4].
What is the Regulatory Status of Tepezza?
Tepezza received FDA approval in January 2020 for the treatment of Thyroid Eye Disease [5].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.fda.gov/drugs/biosimilars/biosimilar-medicines-what-you-need-know
[3] https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-thyroid-eye-disease
[4] https://www.horizontherapeutics.com/
[5] https://www.tepezza.com/
[6] https://www.nei.nih.gov/learn-about-eyes/eye-conditions-and-diseases/thyroid-eye-disease
[7] https://www. Drugs.com/drug-interactions/tepezza.html